Introduction
Campylobacter fetus is a rare etiological agent of neonatal meningitis. However, it is a clinically significant bacterium because many cases of neonatal meningitis caused by C. fetus result in death or severe sequelaen.
Recently, two new carbapenem antibiotics, meropenem (MEPM) and panipenem (PAPM), which possess relatively good ability to penetrate into the cerebrospinal fluid and a lower risk of inducing seizures than imipenem (IPM), have been developed in Japan2,3). We evaluated the in vitro antibacterial activity of the drugs against clinically isolated C. fetus by determining the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC). MEPM and PAPM were found to have strong bacteriostatic and bacteriocidal effects in vitro on the C. fetus clinical isolates. We believe that the drugs are very promising for treatment of neonatal C. fetus meningitis although the safety of the antibiotics has not been established in neonates.
These drugs were well tolerated in infants although the number of clinical trials is still limited8,9). We hope the clinical efficacy and safety of the antibiotics for treatment of C. fetus meningitis in neonates and infants will be confirmed.
